173 related articles for article (PubMed ID: 24516190)
1. A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.
Haig GM; Bain E; Robieson W; Othman AA; Baker J; Lenz RA
Schizophr Bull; 2014 Nov; 40(6):1433-42. PubMed ID: 24516190
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
Haig GM; Wang D; Zhao J; Othman AA; Bain EE
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 28922590
[TBL] [Abstract][Full Text] [Related]
3. The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.
Othman AA; Haig G; Florian H; Locke C; Gertsik L; Dutta S
Br J Clin Pharmacol; 2014 Jun; 77(6):965-74. PubMed ID: 24215171
[TBL] [Abstract][Full Text] [Related]
4. The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
Haig G; Wang D; Othman AA; Zhao J
Neuropsychopharmacology; 2016 Nov; 41(12):2893-2902. PubMed ID: 27319970
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
Haig GM; Bain EE; Robieson WZ; Baker JD; Othman AA
Am J Psychiatry; 2016 Aug; 173(8):827-35. PubMed ID: 26940805
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.
Othman AA; Haig G; Florian H; Locke C; Zhang J; Dutta S
Br J Clin Pharmacol; 2013 May; 75(5):1299-311. PubMed ID: 23016924
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.
Haig GM; Pritchett Y; Meier A; Othman AA; Hall C; Gault LM; Lenz RA
J Alzheimers Dis; 2014; 42(3):959-71. PubMed ID: 25024314
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
Umbricht D; Keefe RS; Murray S; Lowe DA; Porter R; Garibaldi G; Santarelli L
Neuropsychopharmacology; 2014 Jun; 39(7):1568-77. PubMed ID: 24549101
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Brown D; Nakagome K; Cordes J; Brenner R; Gründer G; Keefe RSE; Riesenberg R; Walling DP; Daniels K; Wang L; McGinniss J; Sand M
Schizophr Bull; 2019 Mar; 45(2):350-359. PubMed ID: 29718385
[TBL] [Abstract][Full Text] [Related]
10. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
[TBL] [Abstract][Full Text] [Related]
11. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
F Egan M; Zhao X; Gottwald R; Harper-Mozley L; Zhang Y; Snavely D; Lines C; Michelson D
Schizophr Res; 2013 May; 146(1-3):224-30. PubMed ID: 23523692
[TBL] [Abstract][Full Text] [Related]
12. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial.
Harvey PD; Bowie CR; McDonald S; Podhorna J
Clin Drug Investig; 2020 Apr; 40(4):377-385. PubMed ID: 32036587
[TBL] [Abstract][Full Text] [Related]
14. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia.
Redden L; Rendenbach-Mueller B; Abi-Saab WM; Katz DA; Goenjian A; Robieson WZ; Wang Y; Goss SL; Greco N; Saltarelli MD
J Clin Psychopharmacol; 2011 Apr; 31(2):221-5. PubMed ID: 21346607
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the abuse liability of ABT-288, a novel histamine H₃ receptor antagonist.
Hudzik TJ; Basso A; Boyce-Rustay JM; Bracken W; Browman KE; Drescher K; Esbenshade TA; Loberg LI; Lynch JJ; Brioni JD
Psychopharmacology (Berl); 2013 Jul; 228(2):187-97. PubMed ID: 23455597
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
Buchanan RW; Keefe RS; Lieberman JA; Barch DM; Csernansky JG; Goff DC; Gold JM; Green MF; Jarskog LF; Javitt DC; Kimhy D; Kraus MS; McEvoy JP; Mesholam-Gately RI; Seidman LJ; Ball MP; McMahon RP; Kern RS; Robinson J; Marder SR
Biol Psychiatry; 2011 Mar; 69(5):442-9. PubMed ID: 21145041
[TBL] [Abstract][Full Text] [Related]
18. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.
Fleischhacker WW; Podhorna J; Gröschl M; Hake S; Zhao Y; Huang S; Keefe RSE; Desch M; Brenner R; Walling DP; Mantero-Atienza E; Nakagome K; Pollentier S
Lancet Psychiatry; 2021 Mar; 8(3):191-201. PubMed ID: 33610228
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
